SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?

Shares of Sarepta Therapeutics (SRPT) have risen 23% in the past year, significantly outperforming the industry’s 15.7% decline, as shown in the chart below. During this timeframe, the stock has also outdone the broader Medical sector but slightly underperformed the S&P 500 Index. SRPT’s shares are trading above the 50-day moving average.SRPT Stock PerformanceImage Source: Zacks Investment ResearchThe surge in the stock price can be attributed to the encouraging sales performance of Sarepta’s Duchenne muscu ...